UK paediatric oncology Pneumocystis jirovecii pneumonia surveillance study by Proudfoot, Rebecca Hilary & Phillips, Bob
This is a repository copy of UK paediatric oncology Pneumocystis jirovecii pneumonia 
surveillance study.




Proudfoot, Rebecca Hilary and Phillips, Bob orcid.org/0000-0002-4938-9673 (2021) UK 
paediatric oncology Pneumocystis jirovecii pneumonia surveillance study. Archives of 





This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) 
licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new 
works must also acknowledge the authors and be non-commercial. You don’t have to license any derivative 
works on the same terms. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
1
UK Paediatric Oncology Pneumocystis jirovecii Pneumonia (PJP) Surveillance 
Study
Rebecca Proudfoot, MA (Oxon), MB BS, MRCPCH, PGDip PID (Oxon)1
Bob Phillips, BM BCh, MA, PhD
1 York Teaching Hospital NHS Foundation Trust, UK
2 Centre for Reviews and Dissemination, University of York, York, UK
Correspondence to:
Rebecca Proudfoot, MA (Oxon), MB BS, MRCPCH, PGDip PID (Oxon)
Paediatric Department,





Abstract Word Count: 249
Main Text Word Count: 2582
No of Tables: 1
No of Figures: 2
No of Supporting Information Files: 2
Running Title: Paediatric PJP Surveillance Study




Pneumocystis jirovecii Pneumonia (PJP) is a serious infective complication of 
immunosuppressive therapy.  There are insufficient data concerning the 
incidence or mortality rate in children undergoing treatment for malignancies 
and how these may be influenced by prophylaxis.
Objective:
Prospective collection of clinical information for all suspected and proven 
cases of PJP in children with cancer in the UK and Ireland.
Design:
A surveillance survey was undertaken using a key contact at each paediatric 
oncology Principle Treatment Centre (PTC).
Main Outcome Measures:
To describe the mortality, outcomes and use of prophylaxis in this at-risk 
group.
Results:
The study confirms that PJP is rare, with only 32 cases detected in the UK 
over a 2-year period reported from all 20 PTCs. No deaths were directly 
attributed to PJP, in contrast to previously reported high mortality rates. 
Breakthrough infection may occur despite prescription of ostensibly adequate 
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prophylaxis with co-trimoxazole may occur; 11 such cases were identified. Six 
infections occurred in patients for whom prophylaxis was not thought to be 
indicated. Two infections occurred in patients for whom prophylaxis was 
specifically omitted due to concerns about potential bone marrow suppression 
or delayed engraftment.
Conclusion:
PJP in children treated for malignant disease is rare. Breakthrough infection 
despite prophylaxis with co-trimoxazole may represent pathogen resistance or 
non-compliance. Further consideration of the use of PJP prophylaxis during 
Acute Myeloid Leukaemia and non-Hodgkins Lymphoma treatment is 
warranted, alongside appraisal of the clinical implications of the possible 
marrow suppressive effects of co-trimoxazole and its interactions with 
methotrexate.
BACKGROUND
Pneumocystis jirovecii is an opportunistic parasite that causes pneumonia 
(PJP) in severely immunocompromised hosts. The incidence of PJP among 
HIV negative patients is increasing, perhaps due to more intense and diverse 
immunosuppressive therapies for malignancy, bone marrow and solid organ 
transplants and rheumatological disease.[1] Even with prompt treatment, PJP 
has historically resulted in high mortality rates of 20-60%.[2–4]  There are 
insufficient data concerning the incidence or mortality rates in children being
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treated for malignancies and how these may be influenced by the use of 
prophylaxis.
After dissemination of a recently designed UK guideline for the prophylaxis of 
PJP in children with solid malignancies,[5] a survey of compliance and an 
analysis of PJP cases was undertaken.  
METHODS
This was a national surveillance study of suspected or proven PJP over a 2-
year period, January 2018 – January 2020 in Children’s Cancer and 
Leukaemia Group (CCLG) networked UK paediatric oncology Principle 
Treatment Centres (PTCs). Every quarter, centres reported any suspected or 
proven cases of PJP in the past 3 months with anonymised clinical details 
(Supporting Information, Appendix 1).  
Age and treatment centre were used as identifiers for each case. As PJP is a 
rare condition this was considered sufficient to identify potential duplicates. All 
cases of PJP would be expected to come to the attention of the child’s PTC, 
even if that child presented with symptoms to their local hospital as these 
children’s care is highly centralised.
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Data were collected regarding the diagnosis of PJP, the underlying 
malignancy diagnosis and co-morbidities, the stage in anticancer therapy, the 
total white cell and lymphocyte count at time of presentation with PJP, along 
with the specific use of prophylaxis in the month prior to PJP, and the clinical 
outcome.
Proven PJP was defined on the basis of positive respiratory samples, in a 
clinically relevant setting. Suspected PJP was a clinical diagnosis, based on 
imaging and response to therapy.
RESULTS
All 20 UK PTCs undertook the surveillance. Thirty-two cases (13 suspected, 
19 proven) in 31 patients were identified over the 2-year period. One patient 
with Acute Lymphocytic Leukaemia (ALL) had a second suspected PJP 
infection following a microbiologically confirmed infection 6 months previously.
One case was diagnosed on positive immunofluorescence (IF) on samples 
obtained by bronchoalveolar lavage (BAL). The remaining 18 proven cases 
were diagnosed by Polymerase Chain Reaction (PCR) on samples from BAL, 
blood, sputum and/or nasopharyngeal aspirate. Fourteen of the proven cases 
underwent BAL with positive results (12 PCR positive, 1 IF positive and one IF 
and PCR positive).  No information was recorded regarding suspected cases 
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who underwent BAL with negative microbiology for PJP. The median age was 
9 years 4 months (range 18 months to 18 years).
Of the 20 PTCs, 4 did not report any cases of suspected or proven PJP over 
the 2-year period but the remainder reported between 1 and 4 cases each. 
The spread of suspected versus proven cases at the different PTCs was fairly 
even (see figure 1), suggesting no regional over-reporting or heightened 
awareness.
Table 1 shows the 32 cases by underlying diagnosis, the most common of 
which were haematological malignancies (26/31).
Table 1 PJP cases by underlying diagnosis
Underlying Diagnosis Number of 
Cases




Acute lymphoblastic leukaemia 15 10 in maintenance
3 post allogeneic SCT for 
relapse
1 at initial presentation
1 at presentation with 
2nd relapse post 
allogeneic SCT
Acute myeloid leukaemia 7 2 post allogeneic SCT
3 on MyeChild Protocol
Non-Hodgkins lymphoma 4 All mature B cell NHL 
treated on FAB-LMB 
protocols





FAB-LMB, French-American-British-Lymphoma Malins B, NHL, Non-Hodgkins 
Lymphoma, SCT, Stem Cell Transplant
There were 7 suspected and 8 proven cases of PJP in 14 patients with ALL (1 
patient had a proven infection, followed by a suspected infection 6 months 
later). Of these, 11 cases occurred during maintenance therapy or 
immediately after the end of treatment, 1 presented at diagnosis and was later   
found to have an underlying immunodeficiency, 1 at presentation with a 
second relapse and 2 in the post stem-cell transplant (SCT) phase.
Thirteen of the infections in children with ALL occurred during periods where 
prophylaxis had been prescribed. Four of these episodes were considered by 
their clinical team to be consequent to possible or definite non-compliance 
with prophylaxis.  Five cases were apparent prophylaxis failures on oral co-
trimoxazole, 2 on oral dapsone, one on intravenous pentamidine and one on 
nebulised pentamidine.  Doses of oral co-trimoxazole were all as per the 
UKALL 2011 trial protocol, given on 2 days per week.
There were 7 cases of PJP associated with AML (5 proven, 2 suspected). 
Three were not prescribed any prophylaxis as it was not thought to be 
indicated. One patient was receiving intravenous pentamidine and the 
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remaining 3 co-trimoxazole. Only 1 patient was thought to be non-compliant 
with oral prophylaxis.
There were 3 proven and 1 suspected case of PJP in children with NHL (all 
mature B cell NHL treated on French-American-British-Lymphoma Malins B 
(FAB-LMB) protocols). Only 1 had been prescribed prophylaxis (co-
trimoxazole) as it was felt to be contraindicated with the frequent use of high-
dose (HD) intravenous methotrexate.
The final 6 cases were in 4 patients with neuroblastoma, and 2 in patients with 
sarcomas. The neuroblastoma patients were treated on the European high-
risk neuroblastoma study or CCLG high risk guidelines. Three had received 
an autologous SCT and one had just completed induction therapy. Only 1 
patient was not prescribed any prophylaxis post SCT because of the 
theoretical delay to count recovery. The last 2 patients had relapsed 
rhabdomyosarcoma and Ewing’s sarcoma with suspected and proven PJP 
respectively. The former was prescribed co-trimoxazole but thought not to be 
taking it, and the latter had not been receiving any PJP prophylaxis due to 
concerns about bone marrow suppression.
At presentation with PJP, the mean white cell count and lymphocyte count 
was 4.15 x 109/litre (range 0-14.8) and 0.44 x 109/litre (range 0-1.6) 
respectively for 29 cases (1 case had no blood test results available and a 
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further 2 cases were excluded from analysis as their cell counts may have 
been unreliable at presentation/relapse with leukaemia).  
Most patients (64.5%, 20 out of 31) had no co-morbidities other than their 
underlying malignancy. Only 3 patients had a comorbidity that was identified 
prior to the diagnosis of their malignancy: obesity, trisomy 21, and premature 
birth (28 weeks) with a past history of chronic lung disease.  None had a 
known immunodeficiency prior to their diagnosis of cancer but one patient 
was subsequently found to have mannose binding lectin deficiency.
Gut graft versus host disease (GVHD) has been reported to possibly interfere 
with oral absorption and efficacy of co-trimoxazole[6] but the only patient 
reported as having gut GVHD was prescribed intravenous pentamidine.
Twenty-seven patients (84%) made a full recovery, of whom 11 (34% of total) 
required paediatric intensive care (PICU) admission. There were 3 deaths but 
none of these were considered directly attributable to PJP.
DISCUSSION
PJP remains a rare complication of treatment for malignancy in paediatric 
patients. Only 32 cases were identified in all of the UK PTCs over a 2-year 
period. It is unlikely that any child treated for PJP with an underlying 
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malignancy was omitted from the study due to the centralisation of UK 
children’s cancer services.
It is remarkably challenging to get good denominator data, but we have 
attempted to provide an estimate by extrapolating from recent projections of 
the number of children with cancer treated with systemic anticancer therapy 
each week UK-wide[7]: There are approximately 1700 children undergoing 
chemotherapy each week in the UK, and a similar number may be assumed 
to receive such treatment each year. We identified 16 cases of PJP per year, 
giving an estimated incidence rate of 9.4 per 1000 children treated. This is 
likely to be an overestimate of the true incidence as it is extrapolated from 
Public Health England data for children aged under 16 years and we included 
in our study any young person treated by paediatric oncologists, even if they 
were 16 or older. This may be compared to historical data from the pre-
prophylaxis era of 40.8 per 1000 children treated in one US institution over 9 
years. [8]
The number of apparent co-trimoxazole prophylaxis failures was surprising 
(11 patients), although only prescription, not compliance could be ascertained.  
Early studies of co-trimoxazole prophylaxis used daily dosing regimens and 
reported only 1 case of treatment failure.[4,9,10] However, these early studies 
generally had small numbers of children (80 -229).[9,10] The single case of 
prophylaxis failure was in a child with ALL included in a prospective open 
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study of all confirmed cases of PJP in 3314 children treated in one US 
children’s cancer institution over 3 years.[4] It is difficult to directly compare 
the present data with historical studies as the total number of children given 
prophylaxis over the time period of surveillance is not known.  Furthermore 
these older studies may be underpowered to detect rare events, such as 
prophylaxis failure, or over time it is possible that pathogen resistance is 
emerging.
The optimal dosing schedule for prophylaxis with co-trimoxazole remains to 
be defined. Subsequent to the first randomised controlled trial of daily co-
trimoxazole prophylaxis in children with ALL,[9] studies demonstrated that co-
trimoxazole given on 3 days per week is equally effective.[11] More recently 
other groups have confirmed that cotrimoxazole twice,[12,13] or even once 
weekly [14] has comparable efficacy.  A single case study of once weekly 
prophylaxis failure in a child undergoing allogeneic SCT was reported last 
year and was postulated to be due to poor absorption of co-trimoxazole given 
gastro-intestinal (GI) GVHD.[15] GI GVHD was not reported in any of the 
prophylaxis failures in the present study.  
Only 5 patients were prescribed alternative prophylaxis to co-trimoxazole, 
either dapsone or pentamidine. These are considered less efficacious than 
co-trimoxazole [5,16] but were prescribed due to concerns about bone 
marrow suppression and delayed engraftment.
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Six patients with PJP (5 proven, 1 suspected) were not given prophylaxis as it 
was either not thought to be indicated or was actively contraindicated by 
either local guidance or trial protocol (3 AML and 3 NHL).  A further 
2 patients (1 suspected infection with neuroblastoma and 1 proven infection 
with relapsed Ewing’s sarcoma) were not given any form of prophylaxis due to 
concerns about potential delay in count recovery post SCT, and bone marrow 
suppression respectively.  
In our previously published PJP prophylaxis guideline, [5] we recommended 
against interrupting prophylaxis with co-trimoxazole for patients receiving 
autologous SCT unless there is a delay in engraftment (weak 
recommendation, very low quality evidence). Three studies of low or very low 
quality [4,12,13] considered the frequency of neutropenia in children taking 
co-trimoxazole prophylaxis. Reported rates of presumed co-trimoxazole 
induced neutropenia were only 0.5% to 2%. There exist no studies of the 
effect of co-trimoxazole prophylaxis on time to neutrophil recovery in children 
undergoing SCT. However a retrospective case-control study of 17 adult 
patients showed no difference in time to engraftment following SCT if 
prophylaxis with co-trimoxazole was interrupted versus given 
continuously.[17] The benefit of prophylaxis needs therefore to be balanced 
against a lack of evidence that co-trimoxazole delays engraftment.
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Some centres omit co-trimoxazole in patients receiving HD methotrexate as 
the former is thought to delay the excretion of the latter. At the time of writing 
our guideline, studies on the effect of concurrent co-trimoxazole on 
methotrexate administration were of moderate or low quality and gave 
conflicting results.[18,19] Given the toxicity of delayed methotrexate excretion 
and the challenges of treating raised methotrexate levels, the guideline 
development group and peer review agreed that co-trimoxazole should be 
withheld in patients receiving HD methotrexate. Subsequently a good quality 
prospective study of methotrexate clearance and toxicity in children with ALL 
given HD methotrexate and thrice weekly co-trimoxazole has been 
published.[20] The maximum dose of methotrexate was the same as in the 
UKALL 2011 trial (5 grams/m2 over 24 hours) but the dose of co-trimoxazole 
was greater (75mg/m2 per dose of trimethoprim component 12 hourly on 3 
days per week, opposed to 60mg/m2 12 hourly given in the UK on 2 days per 
week). No evidence was found of an interaction between methotrexate and 
prophylactic co-trimoxazole. In the UK where lower doses of co-trimoxazole 
are prescribed, it can therefore be assumed safe to continue prophylaxis in 
those patients receiving HD methotrexate at doses of 5g/m2 or less. 
Subsequently the Cancer Research UK Clinical Trials Unit (CRCTU) 
amended the UKALL2011 trial protocol in May 2018 to recommend that 
patients should continue co-trimoxazole throughout protocol M and MA.
Of the 3 NHL patients who did not receive any prophylaxis, 2 were on 
protocols that included methotrexate at doses greater than 5g/m2 (8- 16g/m2). 
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If methotrexate doses are higher than 5g/m2, it is still prudent to withhold co-
trimoxazole, but an alternative prophylaxis agent could be considered.
Children with leukaemia have historically been recognised to be high risk for 
PJP.[8,9,21,22] An analysis of all children with PJP at a US children’s 
oncology centre between 1962 and 1971 (pre-prophylaxis) reported incidence 
rates of PJP in 7.7% (41 of 532 children) of ALL and 3.5% (4 out of 113) of 
AML and monomyelocytic leukaemia patients.[8] Underestimation is probable 
as diagnosis was established by identification of organisms in material 
obtained from percutaneous transthoracic needle aspiration of the lung or 
autopsy. Bronchoscopy with BAL and molecular diagnosis is the current gold 
standard for diagnosis and is more sensitive.[23] There is a lack of data, 
subsequent to this publication, on risk for children with AML. The 2016 ECIL 
(European Conference of Infections in Leukaemia) guidelines for PJP 
prophylaxis do not recommend routine prophylaxis for children with AML.[16] 
The Myechild protocol, in agreement with the ECIL guidelines, only 
recommends PJP prophylaxis for those patients receiving fludarabine.[24] In 
our study, 3 patients with AML who had not received fludarabine had proven 
PJP and had not been given any prophylaxis.
Lymphocyte counts alone are considered a poor indication of PJP risk in 
children treated for malignancies.[5] However we identified only 2 patients at 
PJP diagnosis with a lymphocyte count above the lower limit of normal (1.5 x 
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109/l) (see figure 2). As data were not collected on patients without PJP, a 
direct assessment of attributable risk cannot be made, but the finding remains 
supportive of lymphopenia being a risk factor.
There were no deaths directly attributable to PJP in this surveillance study, in 
contrast to high published mortality rates of 20-40% in non-HIV patients 
[4,25–27]. This data is not contemporary and are largely drawn from adult 
populations. Paediatric studies are  historical: the 1973 analysis found a 
mortality rate of 32%  in 41 children with malignancies and PJP treated with 
intravenous pentamidine.[8] A 1975 study of children with ALL found a 
mortality rate of 21% for those treated with intravenous pentamidine and 11% 
for those treated with co-trimoxazole.[21] All the patients in the present study 
received the current standard treatment: high dose intravenous co-
trimoxazole. Pentamidine is less effective as a treatment and other aspects of 
supportive care have improved in recent years. Due to more sensitive 
diagnostic methods and improved awareness of PJP risk, diagnosis is 
probably made more promptly than in the past. Early treatment may contribute 
to the improved survival in our cohort. Half of the patients in our series made 
a full recovery without intensive care support.
CONCLUSION
PJP in children treated for malignant disease is rare, with only 32 suspected 
or confirmed cases detected in the UK over a 2-year period. There were no 
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deaths directly attributable to PJP, in contrast to previously published high 
mortality rates. Breakthrough infection despite prescribed prophylaxis with co-
trimoxazole may represent pathogen resistance or non-compliance with 
prophylactic therapy. Six infections occurred in patients for whom prophylaxis 
was not thought to be indicated and in a further 2 patients for whom no 
prophylaxis was prescribed due to concerns about toxicity. Further 
consideration of the use of PJP prophylaxis during AML and NHL treatment is 
warranted, alongside appraisal of the clinical implications of the possible 
marrow suppressive effects of co-trimoxazole and its interactions with 
methotrexate.
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What is Already Known on This Topic?
PJP is a rare but serious complication of immunosuppressive therapy
Prophylaxis with co-trimoxazole 2 days per week is safe, effective and 
inexpensive
All children with malignancies undergoing immunosuppressive therapy should 
be offered prophylaxis unless there are clear contraindications
What this Study Adds
No deaths were directly attributed to PJP, in contrast to previously reported 
high mortality rates of 20-40%
Breakthrough infection despite prophylaxis with co-trimoxazole is more 
common compared to previously published data
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ABBREVIATIONS
ALL Acute Lymphoblastic Leukaemia
AML Acute Myelocytic Leukaemia
BAL Bronchoalveolar lavage
BC Blood culture
BNF British National Formulary
Bu-Mel Busulphan & mephalan
CCLG Children’s Cancer and Leukaemia Group
CLD Chronic lung disease
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CMV Cytomegalovirus
CYVE Cytarabine & etoposide
Dex Dexamethasone
FLA-Ida Fludarabine, cytarabine, idarubicin
FR Full recovery
GI Gastrointestinal
GVHD Graft versus host disease
HD High Dose
HD-Ara-C High dose cytarabine
HIV Human Immunodeficiency Virus
IF Immunofluorescence
IV Intravenous
LCH Langerhans cell histiocytosis
MA Mitoxantrone & cytarabine
MMF Mycophenolate mofetil
MTX Methotrexate
MUD Matched unrelated donor
NBL Neuroblastoma
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NOPHO Nordic Society for Paediatric Haematology and 
Oncology
PCP Pneumocystis carinii Pneumonia
PCR Polymerase chain reaction
PEG Pegalated
PICU Paediatric intensive care unit
PJP Pneumocystis jirovecii Pneumonia
PTC Primary treatment centre
R-CYM2 Continuous infusion cytarabine & high dose 
methotrexate
RCT Randomised Controlled Trial
RMS Rhabdomyosarcoma
RSV Respiratory syncytial virus
RT Radiotherapy
SCT Stem cell transplant
T21 Trisomy 21
TBI Total body irradiation
TMP-SMX Trimethoprim-sulfamethoxazole
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TPN Total parenteral nutrition
VCR Vincristine
VOD Veno-occlusive disease
WBC White blood cell count
Figure 2 Lymphocyte Counts at Presentation

































Patients, 1 to 29
PJP Surveillance Study Supporting Information Files
Table 2 Acute Lymphoblastic Leukaemia (ALL) Cases





3y, 3m IF on BAL sample Mannose binding 
lectin deficiency
At presentation 7.81 1.8 No n/a FR
18y, 
10m
PCR on BAL 
sample
None UKALL 2011 Reg C 
maintenance
4.37 0.57 TMP-SMX Unsure FR
2y, 6m PCR on BAL 
sample
Failure to thrive, 
on TPN
Interfant 06- maintenance 1.1 0 Dapsone Yes FR
8y, 
11m
PCR on BAL None UKALL 2011 Reg C, high risk 
MRD, had extra therapy 
including NOPHO A and B, 
inotuzamab, blinatuzamab 
and FLA Ida
0.7 0.22 TMP-SMX No PICU with FR
17y, 
7m






UKALL 2011 Reg M 
maintenance
1.5 0.09 Dapsone Yes PICU with FR
3y 11m PCR on BAL Co-incident 
aspergillus and 
stenotrophomonas 
in BC, 2nd relapse
Palliation for refractory ALL, 
over 6m from BMT
1.26 0.31 IV 
pentamidine




PCR on sputum Persistently low 
lymphocyte counts 
in maintenance of 
unknown cause
UKALL2011 Reg B 
maintenance
0.83 0.02 TMP-SMX yes PICU with FR 
4y, 5m PCR on BAL None UKALL2011 Reg B 
maintenance 












A few weeks off treatment, 
(UKALL2011 Regimen B 
stopped early because of 
weight loss and transfusion 
needs)





CXR, CT, response 
to therapy
None UKALL 2011 reg C 
maintenance
7.2 0.45 TMP-SMX Yes PICU with FR
14y, 
6m




UKALL 2011 Reg C 
maintenance








None UKALL 2011 Reg C 
maintenance
3.3 0.24 TMP-SMX unsure FR
10y, 
9m




CXR, response to 
therapy
None UKALL 2011 maintenance 4 0.3 TMP-SMX no FR
10y, 
4m
CXR, CT, response 
to therapy
Mild skin GVHD, 
CMV infection, 
relapsed ALL
Day 22 post SCT 
(cyclophosphamide/TBI)
9.9 0.3 TMP-SMX Yes FR
Table 3 Acute Myeloid Leukaemia (AML) cases





9y, 9m PCR on BAL, CT 
chest
None AML guidelines, following 
cycle 3, HD-Ara-C
0.06 - None - FR
12y, 
7m





10m post 2nd MUD HSCT, on 
ciclosporin & MMF for GVHD 
prophylaxis
12.4 0.4 TMP-SMX no PICU with FR
6y, 7m IF and PCR on 
BAL, CT chest, 
response to 
therapy
None Myechild, post course 2 MA 8.73 1.39 None - FR
14y, 
4m
PCR on BAL None MyeChild 01, post cycle 1 
(one dose of gemtuzumab 
with MA) day 22
1.6 1.6 none - PICU with FR
11y, 
7m
PCR on BAL, CT 
chest
None MyeChild 01, post cycle 2 – 
FLA-Ida day 43









None Post FLA 0.1 0 TMP-SMX yes FR





Day 39 post HSCT. Reduced 
intensity pretransplant 
conditioning with busulfan 
and fludarabine
14.8 1.3 IV 
pentamidine
yes Death more likely 
due to other causes
Table 4 Non-Hodgkin’s Lymphoma (NHL) Cases





6y, 8m PCR from NPA & 
blood
None Inter-rituximab study, 
Group C, completed 
induction and 
consolidation, due to start 
maintenance
<0.1 0.01 no No FR
14y, 
11m
PCR on BAL None Inter B 2010 with 
rituximab, stopped post 
CYVE 1 due to toxicity
4.9 0.06 TMP-SMX yes PICU with FR
3y, 7m PCR on NPA None Inter-BNHL Group B with 
rituximab R-CYM2 day 21
Unknown Unknown No No FR
Suspected Infections




28 weeks, CLD 
resolved by 18m
Group C- CYVE 2 day 10 3.2 0.23 No No FR
Table 5 Neuroblastoma Cases





1y, 6m PCR on sputum 
and NPA
None European HR 
neuroblastoma study, 1st
cycle cis-retinoic acid post 
autologous SCT
6.5 0.45 TMP-SMX Yes PICU with FR
2y 2m PCR on BAL 
sample
None CCLG guidelines for HR 
neuroblastoma. Post-
surgical resection
5.8 0.31 TMP-SMX Yes PICU with FR
Suspected Infections





neuroblastoma study, Day 
38 post autologous SCT 
(BuMel conditioning)
2.4 0.6 no n/a FR
2y, 9m CXR None European HR 
neuroblastoma study, Day 
35 post autologous SCT 
(BuMel conditioning)
3.4 0.6 TMP-SMX Yes PICU with FR
Table 6 Rhabdomyosarcoma













and fenofibrate, with 




palliative radiotherapy to 
spine
2.09 0.75 TMP-SMX No PICU with FR
Table 7 Ewing’s sarcoma
















B12 and folic 
acid deficiency 
with some GI 
intolerance
On oral Etoposide 
following wedge resection 
3.9 0.4 no n/a PICU with FR
Table 8 No Prophylaxis Prescribed
Underlying Diagnosis PJP diagnosis Protocol Reason for no prophylaxis
ALL proven At diagnosis At diagnosis
Relapsed ALL suspected At relapse At relapse
AML proven AML guidelines, following cycle 3, HD-Ara-C Not routinely prescribed for AML at this 
PTC
AML proven Myechild, post course 2 MA Not indicated by Myechild protocol
AML proven MyeChild 01, post cycle 1 (one dose of gemtuzumab with 
MA) day 22
Not indicated by Myechild protocol
NHL proven Inter-rituximab study, Group C, completed induction and 
consolidation, due to start maintenance
Not thought indicated
NHL suspected Group C- CYVE 2 day 10 Not thought indicated
NHL proven Inter-BNHL Group B with rituximab R-CYM2 day 21 Not thought indicated
Neuroblastoma suspected European HR neuroblastoma study, Day 38 post 
autologous SCT (BuMel conditioning)
Not given post SCT because of theoretical 
delay to count recovery
Relapsed Ewing’s proven On oral Etoposide following wedge resection Concerns regarding bone marrow 
suppression given past episodes of severe 
febrile neutropaenia
Table 9 Co-trimoxazole prophylaxis failure (non-compliance not confirmed)
Underlying Diagnosis Age PJP Diagnosis Protocol Outcome
ALL 10y, 4m Suspected UKALL 2011 Reg C maintenance PICU with FR
ALL 14y, 6m Suspected UKALL 2011 Reg C maintenance Death more likely from other causes
Relapsed ALL 10ym 4m Suspected Day 22 post SCT (cyclophosphamide/TBI) FR
ALL 4y, 10m Proven UKALL 2011 Reg B maintenance PICU with FR
ALL 4y, 5m Proven UKALL 2011 Reg B maintenance FR
Neuroblastoma 2y, 9m Suspected European HR neuroblastoma study, Day 35 post 
autologous SCT (BuMel conditioning)
PICU with FR
Neuroblastoma 2y 2m Proven Post surgical resection PICU with FR
Neuroblastoma 1y, 6m Proven European HR neuroblastoma study, 1st cycle cis-
retinoic acid post autologous SCT
PICU with FR
AML 15y, 8m Suspected Post FLA FR
AML 11y, 7m Proven MyeChild 01, post cycle 2 – FLA-Ida day 43 AML disease progression, ongoing O2 
requirement, palliative care
NHL 14y, 11m Proven Inter B 2010 with rituximab, stopped post CYVE 1 
due to toxicity
PICU with FR
Table 10: Age, Non-compliance and Prophylaxis Failure
Range
Mean Average Age of all 32 Presentations 9 years and 3 months
Median Age of all 32 Presentations 9 years and 4 months
18 months to 18 year and 10 months
Average Age of Non-compliant Patients (N=5) 14 years and 6 months 8 years 11 months to 18 years 10 
months
Average Age of Remaining 27 Presentations 9 years and 3 months 18 months to 18 years and 2 months
Average age of co-trimoxazole failures (N=11) 8 years and 5 months 18 months to 15 years and 8 months
Abbreviations
ALL Acute Lymphoblastic Leukaemia
AML Acute Myelocytic Leukaemia
BAL Bronchoalveolar lavage
BC Blood culture
BNF British National Formulary
Bu-Mel Busulphan & mephalan
CCLG Children’s Cancer and Leukaemia Group
CLD Chronic lung disease
CMV Cytomegalovirus
CYVE Cytarabine & etoposide
Dex Dexamethasone
FLA-Ida Fludarabine, cytarabine, idarubicin
FR Full recovery
GI Gastrointestinal
GVHD Graft versus host disease
HD High Dose
HD-Ara-C High dose cytarabine
HIV Human Immunodeficiency Virus
IF Immunofluorescence
IV Intravenous
LCH Langerhans cell histiocytosis
MA Mitoxantrone & cytarabine
MMF Mycophenolate mofetil
MTX Methotrexate
MUD Matched unrelated donor
NBL Neuroblastoma
NOPHO Nordic Society for Paediatric Haematology and Oncology
PCP Pneumocystis carinii Pneumonia
PCR Polymerase chain reaction
PEG Pegalated
PICU Paediatric intensive care unit
PJP Pneumocystis jirovecii Pneumonia
PTC Primary treatment centre
R-CYM2 Continuous infusion cytarabine & high dose methotrexate
RCT Randomised Controlled Trial
RMS Rhabdomyosarcoma
RSV Respiratory syncytial virus
RT Radiotherapy
SCT Stem cell transplant
T21 Trisomy 21
TBI Total body irradiation
TMP-SMX Trimethoprim-sulfamethoxazole
TPN Total parenteral nutrition
VCR Vincristine
VOD Veno-occlusive disease
WBC White blood cell count
PJP Surveillance Study, Chief Investigator Dr Rebecca Proudfoot, Rebecca.proudfoot1@nhs.net
Pneumocystis jirovecii Pneumonia (PJP) Surveillance Questionnaire
Please complete if you have seen a patient with suspected or proven PJP 
(previously known as Pneumocystis carinii Pneumonia, PCP) in the last 3 months:
1. Age in years and months
2. Primary Treatment Centre
3. Suspected or proven diagnosis of PJP?
4. If suspected, was this on the basis of: 
(tick all that apply) i.  CXR appearance                  
ii.  CT chest appearance          
iii.  Response to therapy          
iv.  Other – please specify:   
5. If proven, what positive samples were 
obtained?
6. Underlying malignant diagnosis
7. Other relevant co-morbidities (e.g. 
immunodeficiency, bronchiectasis):
8. Treatment Protocol/Trial and place in protocol 
(e.g. Wk145 maintenance, D+45 BuMel HSCT, 
3 weeks after EoT) 
9. White cell count & lymphocyte count at 
presentation with recognised PJP:
10. Was the patient prescribed PJP prophylaxis in 
the month prior to PJP diagnosis?
1.  Yes       : Go to Q 11, 12 & 14  
2.  No        : Go to Q 13 & 14
3.  Unsure : Go to Q 14
11. What form of prophylaxis was prescribed (tick 
all that may apply)?
a.  Enteral co-trimoxazole
Please specify dose/regimen in 
comments underneath (for example as 
per UKALL2011, 2 days per week*)
b.  Parenteral co-trimoxazole
c.  Nebulised pentamidine
d.  Intravenous pentamidine
e.  Dapsone
f.  Atovaquone
PJP Surveillance Study, Chief Investigator Dr Rebecca Proudfoot, Rebecca.proudfoot1@nhs.net
g.  Other – please specify
h.  Unknown
Comments:
12. Do you believe the patient was receiving and 
taking the prescribed prophylaxis in the month 





13. Please tick all the reasons that apply as why 
prophylaxis was not prescribed:
a.  Not thought to be indicated by 
physician
b.  Parental or patient active choice 
c.  Error (i.e. not considered by medical 
team)
d.  Allergy/ intolerance – please specify 
to which drug
e.  Other – please specify:
14. Clinical outcome (please tick all that apply): a.  Full recovery
b.  PICU admission with recovery
c.  Death probably attributable to PJP
d.  Death more likely attributable to                 
other causes
e.  Unknown
f.  Not yet established
Any Further Comments:
*Co-trimoxazole dosing as per UKALL2011







Twice Daily on 2 
consecutive 
days per week
